Table 31.4—Antipsychotic Agents for the Treatment of Psychosis (Hallucinations and Delusions) in Dementia
|
Drug |
Daily Dose |
Adverse Effects |
Comments |
Formulations |
|
AripiprazoleOL |
5–15 mg |
Mild sedation, mild hypotension |
Warning about increased cerebrovascular events in dementia, possible hyperglycemia |
Tablet, liquid concentrate |
|
ClozapineOL |
12.5–200 mg |
Sedation, hypotension, anticholinergic effects, agranulocytosis |
Weekly CBCs required, poorly tolerated by older adults, reserved for treatment of refractory cases, warning about hyperglycemia |
Tablet, rapidly dissolving tablet |
|
OlanzapineOL |
2.5–10 mg |
Sedation, falls, gait disturbance |
Warning about hyperglycemia and cerebrovascular events in patients with dementia |
Tablet, rapidly dissolving tablet, IM injection |
|
QuetiapineOL |
25–200 mg |
Sedation, hypotension |
Warning about hyperglycemia, ophthalmologic exam recommended every 6 months |
Tablet |
|
RisperidoneOL |
0.5–2 mg |
Sedation, hypotension, EPS with doses > 1 mg/day |
Warning about cerebrovascular events in patients with dementia, hyperglycemia warning |
Tablet, rapidly dissolving tablet, liquid concentrate, depot IM injection |
|
ZiprasidoneOL |
40–160 mg |
Higher risk of QTc prolongation |
Warning regarding increased QTc prolongation, possible hyperglycemia Little published information on use in older adults |
Capsule, IM injection |
NOTE: CBCs = complete blood cell counts; EPS = extrapyramidal symptoms; IM = intramuscular.